Abstract:Owing to its roles in human health and disease, the modification of nuclear, cytoplasmic, and mitochondrial proteins with O-linked N-acetylglucosamine residues (O-GlcNAc) has emerged as a topic of great interest. Despite the presence of O-GlcNAc on hundreds of proteins within cells, only two enzymes regulate this modification. One of these enzymes is O-GlcNAcase (OGA), a dimeric glycoside hydrolase that has a deep active site cleft in which diverse substrates are accommodated. Chemical tools to control OGA are emerging as essential resources for helping to decode the biochemical and cellular functions of the O-GlcNAc pathway. Here we describe rationally designed bicyclic thiazolidine inhibitors that exhibit superb selectivity and picomolar inhibition of human OGA. Structures of these inhibitors in complex with human OGA reveal the basis for their exceptional potency and show that they extend out of the enzyme active site cleft. Leveraging this structure, we create a high affinity chemoproteomic probe that enables simple one-step purification of endogenous OGA from brain and targeted proteomic mapping of its post-translational modifications. These data uncover a range of new modifications, including some that are less-known, such as O-ubiquitination and N-formylation. We expect that these inhibitors and chemoproteomics probes will prove useful as fundamental tools to decipher the mechanisms by which OGA is regulated and directed to its diverse cellular substrates. Moreover, the inhibitors and structures described here lay out a blueprint that will enable the creation of chemical probes and tools to interrogate OGA and other carbohydrate active enzymes.

Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold.

Spatiotemporal Activation of Protein O-GlcNAcylation in Living Cells.

Identification of a Specific Inhibitor of Noga — a Caspase-3 Cleaved O-GlcNAcase Variant During Apoptosis

Design and synthesis of O-GlcNAcase inhibitors via 'click chemistry' and biological evaluations.

Modification of the Thioglycosyl-Naphthalimides As Potent and Selective Human O-GlcNAcase Inhibitors.

Design and Optimization of Thioglycosyl–naphthalimides As Efficient Inhibitors Against Human O-GlcNAcase

Bicyclic Picomolar OGA Inhibitors Enable Chemoproteomic Mapping of Its Endogenous Post-translational Modifications

Virtual Screening of Human O-Glcnac Transferase Inhibitors

Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation

Activity Based High-Throughput Screening for Novel O-GlcNAc Transferase Substrates Using a Dynamic Peptide Microarray

Elucidating the protein substrate recognition of O-GlcNAc transferase (OGT) toward O-GlcNAcase (OGA) using a GlcNAc electrophilic probe

Synthesis of NAM-thiazoline Derivatives As Novel O-GlcNAcase Inhibitors.

Production of Glycopeptide Derivatives for Exploring Substrate Specificity of Human OGA Toward Sugar Moiety

Discovery of a Low Toxicity O-GlcNAc Transferase (OGT) Inhibitor by Structure-based Virtual Screening of Natural Products

Mechanistic Insights into the Hydrolysis of O-GlcNAcylation Catalyzed by Human O-GlcNAcase.

A DNA Nanoscaffold-Based Electrochemical Assay for Sensitive Determination of O-GlcNAc Transferase (OGT) Activity and Its Application in Cell-Permeable OGT Inhibitors Screening

Identification of a Diketopiperazine-Based O-GlcNAc Transferase Inhibitor Sensitizing Hepatocellular Carcinoma to CDK9 Inhibition.

New ELISA-based Method for the Detection of O-GlcNAc Transferase Activity in Vitro

Discovery and Activity Verification of a O-GlcNAc Transferase Inhibitor by Structure-based Virtual Screening

Ac4GlcNAcF3, an OGT-tolerated but OGA-resistant Regulator for O-GlcNAcylation.

Isoindoline-based fluorogenic probes bearing a self-immolative linker for the sensitive and selective detection of O-GlcNAcase activity